Figures
Figure 1. – Histogram showing induction therapy use (%) by transplant centers
Figure 2. – Postoperative outcomes stratified by induction therapy terciles
Figure 3. - Treated-acute rejection rate at 1-year post-OHT stratified by center-level induction therapy terciles. Each circle represents an individual center.
Figure 4. – Center-level correlation between treated-acute rejection rate at 1 year and induction therapy utilization stratified by the baseline recipient pre-OHT rejection risk scores. Each circle represents an individual center.
References
1. Enderby C, Keller CA. An overview of immunosuppression in solid organ transplantation. Am J Manag Care. 2015 Jan;21(1 Suppl):s12-23.
2. Zuckermann A, Schulz U, Deuse T, Ruhpawar A, Schmitto JD, Beiras-Fernandez A, et al. Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression. Transpl Int. 2015 Mar;28(3):259–69.
3. Wang S-S, Chou N-K, Chi N-H, Huang S-C, Wu I-H, Wang C-H, et al. The survival of heart transplant recipients using cyclosporine and everolimus is not inferior to that using cyclosporine and mycophenolate. Transplant Proc. 2010 Apr;42(3):938–9.
4. Weber BN, Kobashigawa JA, Givertz MM. Evolving Areas in Heart Transplantation. JACC Hear Fail. 2017 Dec 1;5(12):869–78.
5. Almenar L, García-Palomar C, Martínez-Dolz L, Chamorro C, Moro J, Zorio E, et al. Influence of induction therapy on rejection and survival in heart transplantation. Transplant Proc. 2005 Nov;37(9):4024–7.
6. Mehra MR, Zucker MJ, Wagoner L, Michler R, Boehmer J, Kovarik J, et al. A Multicenter, Prospective, Randomized, Double-Blind Trial of Basiliximab in Heart Transplantation. J Hear Lung Transplant. 2005 Sep 1;24(9):1297–304.
7. Hershberger RE, Starling RC, Eisen HJ, Bergh C-H, Kormos RL, Love RB, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med. 2005 Jun 30;352(26):2705–13.
8. Hao W-J, Zong H-T, Cui Y-S, Zhang Y. The Efficacy and Safety of Alemtuzumab and Daclizumab Versus Antithymocyte Globulin During Organ Transplantation: A Meta-Analysis. Transplant Proc. 2012 Dec 1;44(10):2955–60.
9. Higgins R, Kirklin JK, Brown RN, Rayburn BK, Wagoner L, Oren R, et al. To induce or not to induce: Do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy? J Hear Lung Transplant. 2005 Apr;24(4):392–400.
10. Kilic A, Weiss ES, Allen JG, Conte J V., Shah AS, Baumgartner WA, et al. Simple Score to Assess the Risk of Rejection After Orthotopic Heart Transplantation. Circulation. 2012 Jun 19;125(24):3013–21.
11. Costanzo MR, Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. Vol. 29, The Journal of Heart and Lung Transplantation. 2010. p. 914–56.
12. Shuhaiber JH, Moore J, Dyke DB. The effect of transplant center volume on survival after heart transplantation: A multicenter study. J Thorac Cardiovasc Surg. 2010;
13. Arnaoutakis GJ, George TJ, Allen JG, Russell SD, Shah AS, Conte J V., et al. Institutional volume and the effect of recipient risk on short-term mortality after orthotopic heart transplant. J Thorac Cardiovasc Surg. 2012 Jan;143(1):157-167.e1.
14. Kilic A, Weiss ES, Yuh DD, Shah AS, Cameron DE, Baumgartner WA, et al. Institutional Factors Beyond Procedural Volume Significantly Impact Center Variability in Outcomes After Orthotopic Heart Transplantation. Ann Surg. 2012 Oct;256(4):616–23.
15. Austin PC, Merlo J. Intermediate and advanced topics in multilevel logistic regression analysis. Stat Med. 2017 Sep 10;36(20):3257–77.
16. Bittermann T, Hubbard RA, Lewis JD, Goldberg DS. The use of induction therapy in liver transplantation is highly variable and is associated with posttransplant outcomes. Am J Transplant. 2019 Dec 17;19(12):3319–27.
17. Dharnidharka VR, Naik AS, Axelrod DA, Schnitzler MA, Zhang Z, Bae S, et al. Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice. Transpl Int. 2018 Feb;31(2):198–211.
18. Briasoulis A, Inampudi C, Pala M, Asleh R, Alvarez P, Bhama J. Induction immunosuppressive therapy in cardiac transplantation: a systematic review and meta-analysis. Heart Fail Rev. 2018 Sep 13;23(5):641–9.
19. Penninga L, Møller CH, Gustafsson F, Gluud C, Steinbrüchel DA. Immunosuppressive T-cell antibody induction for heart transplant recipients. Cochrane Database Syst Rev. 2013 Dec 2;
20. Amin AA, Araj FG, Ariyamuthu VK, Drazner MH, Ayvaci MUS, Mammen PPA, et al. Impact of induction immunosuppression on patient survival in heart transplant recipients treated with tacrolimus and mycophenolic acid in the current allocation era. Clin Transplant. 2019;
21. Whitson BA, Kilic A, Lehman A, Wehr A, Hasan A, Haas G, et al. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents. Clin Transplant. 2015 Jan;29(1):9–17.